CD274 and neoplasm: The median OS in patients with < 1% versus ≥ 1% tumor PD-L1 expression was 13.4 months (95% CI 8.84–17.05) versus 12.75 months (9.92–17.84), respectively, with nivolumab and 10.32 months (7.39–13.67) versus 8.38 months (5.98–9.89), respectively, with chemotherapy.